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Introduction
Osteoarthritis (OA), the most common degenerative joint disorder, places an enormous financial burden on 
the health care system and results in marked disability in the population (1–4). By the year 2030, nearly 67 
million people will be suffering from OA across the United States (5). Currently, knee and hip OA is diag-
nosed by radiographs showing significant articular cartilage loss, joint space narrowing, subchondral bone 
sclerosis, osteophytes, extremity deformity, and severe inflammation. There are no effective disease-modify-
ing treatments for OA other than pain management and end-stage surgical interventions (6–8). Thus, there 
is an urgent unmet clinical need to develop mechanistically based therapeutic strategies to treat this disease.
Although OA is a disease affecting the whole joint, articular cartilage destruction is considered the 
primary pathological change related to symptoms and disability (9). Numerous GWAS have examined 
gene sequence changes that might predispose individuals to develop OA. Although several gene mutations 
and single nucleotide polymorphisms have been identified, alterations in DNA base sequences account for 
the minority of  cases of  osteoarthritis across the population (10–15). More recently, the role of  epigenetics 
in the modulation of  gene expression and in the pathogenesis of  human diseases has been recognized. 
Epigenetic changes involve alterations in the structure of  DNA rather than the genetic sequence. The 3 
main categories of  epigenetic regulation are histone modification (methylation, acetylation, etc.), DNA 
methylation, and small noncoding RNAs. Epigenetic events that influence gene expression are known to 
be controlled by aging, disease, and environmental factors, including obesity, smoking, and injury (16–19).
We recently reported that Dnmt3b, one of  the DNA methyltransferases, is highly expressed in healthy 
murine and human cartilage. Our work further established that Dnmt3b loss of  function (LOF) in articular 
Recently we demonstrated that ablation of the DNA methyltransferase enzyme, Dnmt3b, 
resulted in catabolism and progression of osteoarthritis (OA) in murine articular cartilage 
through a mechanism involving increased mitochondrial respiration. In this study, we identify 
4-aminobutyrate aminotransferase (Abat) as a downstream target of Dnmt3b. Abat is an enzyme 
that metabolizes γ-aminobutyric acid to succinate, a key intermediate in the tricarboxylic acid 
cycle. We show that Dnmt3b binds to the Abat promoter, increases methylation of a conserved 
CpG sequence just upstream of the transcriptional start site, and inhibits Abat expression. Dnmt3b 
deletion in articular chondrocytes results in reduced methylation of the CpG sequence in the 
Abat promoter, which subsequently increases expression of Abat. Increased Abat expression in 
chondrocytes leads to enhanced mitochondrial respiration and elevated expression of catabolic 
genes. Overexpression of Abat in murine knee joints via lentiviral injection results in accelerated 
cartilage degradation following surgical induction of OA. In contrast, lentiviral-based knockdown 
of Abat attenuates the expression of IL-1β–induced catabolic genes in primary murine articular 
chondrocytes in vitro and also protects against murine articular cartilage degradation in vivo. 
Strikingly, treatment with the FDA-approved small-molecule Abat inhibitor, vigabatrin, significantly 
prevents the development of injury-induced OA in mice. In summary, these studies establish Abat 
as an important new target for therapies to prevent OA.
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chondrocytes leads to OA progression, at least in part, because of  accelerated tricarboxylic acid (TCA) 
cycle and elevated mitochondrial respiration (20). Interestingly, increasing evidence implicates an asso-
ciation between increased mitochondrial respiration and cartilage catabolism leading to OA. Specifical-
ly, chondrocytes with an OA-like catabolic phenotype transition to oxidative phosphorylation to produce 
ATP, in contrast with healthy articular chondrocytes that rely on glycolysis to maintain a homeostatic state 
(21–25). However, the molecular mechanisms and targets involved in the shift toward oxidative phosphor-
ylation in chondrocytes in OA are not known. In the current study, the integrative analysis of  RNA-Seq 
and DNA Methyl-Seq (whole genome bisulfite DNA methylation sequencing) data from Dnmt3b LOF 
chondrocytes reveals that the enzyme 4-aminobutyrate aminotransferase (Abat) not only is upregulated in 
OA but also is one of  the downstream targets of  Dnmt3b. Abat is a critical enzyme responsible for catabo-
lism of  γ-aminobutyric acid (GABA) to succinate (26), an important metabolite in the TCA cycle. Elevated 
succinate levels enhance the TCA cycle and lead to increased mitochondrial respiration (27).
Human patients with Abat deficiency are diagnosed with cognitive disorders and seizures (27–29). 
Multiple pharmacological compounds have been developed to target Abat-related pathways to treat these 
neurological conditions (30–32). In the current study, we examine the role of  Abat in the pathogenesis of  
OA and explore the potential of  vigabatrin, an FDA-approved small-molecule Abat inhibitor, to prevent 
the development of  OA in mice following joint injury. Our data indicate that both Abat and mitochondrial 
metabolism by oxidative phosphorylation are novel targets for the prevention and treatment of  OA.
Results
Abat is the downstream target of  Dnmt3b in chondrocytes. Our recent findings demonstrated that Dnmt3b gene 
deletion in chondrocytes leads to a catabolic phenotype in vitro and results in spontaneous articular cartilage 
degeneration in the knee joints of  mice (20). RNA-Seq and DNA Methyl-Seq analyses showed enrichment 
of  differentially expressed genes involved in cellular metabolic processes in articular chondrocytes with 
Dnmt3b gene deletion. In particular, TCA cycle metabolites and mitochondrial respiration were elevated in 
Dnmt3b LOF chondrocytes (20). Given that Dnmt3b broadly targets the whole genome and thus may not 
be an effective therapeutic target, we further examined downstream genes showing both differential expres-
sion and methylation patterns in the promoter regions of  articular chondrocytes following Dnmt3b LOF. In 
the current study, we report 44 gene candidates that not only displayed altered expression levels in Dnmt3b 
LOF chondrocytes but whose promoters also contained alterations in levels of  DNA methylation (see Sup-
plemental Table 1; supplemental material available online with this article; https://doi.org/10.1172/jci.
insight.128568DS1). Two-thirds of  the candidate genes contained hypomethylated promoter CpG regions, 
including those known to be altered in OA, such as Wif1 (33), Mmp3, and Adam12. Among the remaining 
genes, we selected Abat, the gene encoding the enzyme Abat for further study because of  its potential role 
in regulating metabolism, and it has not been studied before in the context of  cartilage biology to our 
knowledge. Abat functions to catalyze GABA into succinic semialdehyde, the latter of  which can be fur-
ther oxidized to succinate and enter the TCA cycle (34). We first supported our sequencing data by direct 
analysis of  the Abat promoter and confirmed that Dnmt3b LOF resulted in reduced methylation in this 
region (Figure 1A) and established that the decrease in methylation likely results in upregulation of  Abat 
expression in articular chondrocytes (Figure 1B). Our previous observation of  increased succinate levels in 
Dnmt3b LOF chondrocytes (20) suggested that the increase in Abat expression may have functional signif-
icance. We next addressed whether Dnmt3b is directly involved in the transcriptional regulation of  Abat. A 
342-bp CpG island was identified in the proximal promoter of  Abat, and ChIP assays showed that Dnmt3b 
binds specifically to this conserved CpG island of  Abat in ATDC5 cells (Figure 1C). To determine the func-
tional role of  Dnmt3b binding, we overexpressed Dnmt3b in chondrocytes, and, as expected, expression of  
Abat decreased as a result (Figure 1D). We previously showed that DNMT3B is decreased in human OA 
articular cartilage (20), and we further show here that this decrease is associated with a significant increase 
in ABAT expression in OA cartilage from human patients with OA (Figure 1E). Chondrocytes were isolat-
ed from patients with OA and treated with IL-1β, which has been shown to increase cartilage catabolism 
and reduce the expression of  Dnmt3b in articular chondrocytes (20). Treatment of  human chondrocytes 
with IL-1β resulted in upregulation of  ABAT mRNA expression (Figure 1F). In addition, a robust increase 
in Abat mRNA and protein expression was also found in murine cartilage tissue 4 weeks after meniscal 
ligament injury (MLI) surgery (Figure 1G). Altogether, these results show that the decrease in Dnmt3b 
expression observed in OA results in reduced methylation of  the Abat promoter and a concomitant increase 
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in Abat gene and protein expression.
Abat overexpression leads to chondrocyte hypertrophy in vitro and accelerated OA progression in mice. To estab-
lish the potential role of  Abat as a regulator of  cellular metabolism and homeostasis, we used lentivirus to 
overexpress Abat in primary murine articular chondrocytes. Similar to Dnmt3b LOF, lenti-Abat infection 
enhanced mitochondrial respiration, as reflected by increased basal and maximal oxygen consumption rate 
(OCR) in articular chondrocytes (Figure 1H). Moreover, overexpression of  Abat in articular chondrocytes 
induced catabolic gene expression, including Runx2 and Mmp13, which is consistent with chondrocyte 
hypertrophy (Figure 1I). We then directly injected lenti-Abat into murine knee joints immediately following 
MLI surgery to determine whether Abat overexpression could accelerate cartilage degeneration in mice. 
Intra-knee injection resulted in successful transduction of  lentivirus into cells of  the knee joint in vivo (Sup-
plemental Figure 1, A and C), and about 40% of  articular chondrocytes were infected by lenti-Flag and 
Lenti-Abat virus (Supplemental Figure 1B). At 4 weeks following MLI, articular cartilage in control animals 
transduced with lenti-Flag remained intact, with no structural changes observed in the subchondral bone. In 
contrast, the overexpression of  Abat in murine knee joints resulted in apparent damage of  cartilage tissue 4 
weeks following MLI surgery as shown by reduced proteoglycan staining and loss of  cartilage tissue (Figure 
2A). Additionally, although subchondral bone structure, including bone density and trabecular properties, 
was similar to control mice (Figure 2B and Supplemental Figure 2, A and B), 6 out of  7 mouse knee joints 
injected with lenti-Abat developed osteophytes adjacent to the medial tibial plateau (Supplemental Figure 
2C), consistent with an OA phenotype. The accelerated OA progression in lenti-Abat–infected knees was 
further shown by an increase in the OARSI score and decrease in the cartilage area compared with mice 
infected with lenti-Flag virus (Figure 2, C and D). To examine specific changes in extracellular matrix, 
expression of  Prg4, Col10A1, and Mmp13 was analyzed in articular cartilage tissue from lenti-Flag– and 
lenti-Abat–infected knees. Immunostaining data showed markedly reduced Prg4 expression, especially in the 
superficial layer of  lenti-Abat–infected cartilage. In addition, abundant staining for Mmp13 and Col10A1 
was detected in the cartilage tissue of  lenti-Abat–infected mice, compared with minimal expression levels 
observed in control mice infected with lenti-Flag virus (Figure 2E). The cartilage change and ectopic bone 
formation induced by Abat overexpression in murine knee joints suggest disruption of  homeostasis toward 
a more catabolic state and that elevated levels of  Abat may contribute to the development or accelerated 
progression of  OA.
Inhibition of  Abat in vivo attenuates OA progression. Because Abat overexpression led to a catabolic 
phenotype in chondrocytes associated with increased mitochondria respiration in vitro and acceler-
ated progression of  OA in vivo, we next determined whether Abat inhibition could attenuate these 
effects. Primary murine articular chondrocyte cultures were infected with either control lenti-GFP or 
lenti-shAbat virus to suppress Abat expression. As expected, both basal and maximal mitochondrial 
respiration were suppressed by Abat inhibition (Figure 3A and Supplemental Figure 3). Articular 
chondrocytes were also treated with IL-1β, to induce a catabolic phenotype. Transduction of  cells 
with lenti-shAbat inhibited the increase in Col10a1, Runx2, and Mmp13 expression induced by IL-1β 
treatment (Figure 3B). To determine whether Abat inhibition could also reduce chondrocyte catabo-
lism in vivo, murine knee joints were injected with lenti-GFP or lenti-shAbat following MLI surgery. 
Supplemental Figure 4 shows that chondrocytes in articular cartilage of  the treated knee joints were 
successfully transduced as shown by positive GFP expression. The lenti-GFP control mice exhibited 
advanced osteoarthritic changes with loss of  proteoglycan and the presence of  cartilage surface fibril-
lations at 10 weeks after MLI. In contrast, cartilage destruction was attenuated in knee joints infected 
Figure 1. Abat is a target of Dnmt3b, and Abat overexpression induces chondrocyte hypertrophy. Dnmt3b LOF leads to DNA hypomethylation (A) and 
increased Abat expression (B) in murine chondrocytes (n = 3). (C) Pull-down assay of genomic DNA with a Dnmt3b antibody (ChIP assay) shows interaction of 
Dnmt3b with its binding site in the Abat promoter region by quantitative PCR (qPCR) using specific primers (n = 3). (D) Real-time qPCR analysis of Dnmt3b 
and Abat in articular chondrocytes transduced with either lentivirus Dnmt3b (lenti-Dnmt3b) or control virus. (E) Human OA chondrocytes exhibit low ABAT 
expression compared with nondiseased (ND) chondrocytes (n = 3), and (F) induction of human chondrocytes (n = 3) with IL-1β results in decreased expression 
of ABAT mRNA. (G) Abat mRNA and protein expression is decreased in MLI cartilage compared with sham surgery cartilage in gene and protein levels (n = 5) 
2 weeks after MLI surgery. (H) Mitochondrial respiration was measured by the Seahorse XF Extracellular Flux Analyzer. Basal respiration and maximal respi-
ration, as measured by the oxygen consumption rate (OCR), are shown (n = 8). (I) Real-time qPCR analyses of gene expression from articular chondrocytes 
transduced with either lenti-Abat or control virus (n = 3). *P < 0.05 by 2-tailed Student’s t test.
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Figure 2. Abat overexpression accelerates OA pro-
gression in mice. MLI or sham surgeries were per-
formed on right knee joints followed by intra-artic-
ular injection of lenti-Abat (Abat gain of function 
[GOF]) or lenti-Flag (control). (A) Representative 
images of histological sections of control and Abat 
GOF knee joints at 4 weeks following MLI surgery 
(n = 7). (B) Ratios of bone volume to total volume 
(BV/TV) of tibial subchondral bone were calculated 
from the micro-CT images (n = 7). Quantification 
of histological assessment by Osteoarthritis 
Research Society International (OARSI) scoring (C) 
and cartilage area (D) (n = 7). (E) Immunohisto-
chemical analyses for Prg4, Mmp13, and Col10A1 on 
knee sections of control and Abat GOF cartilage. 
*P < 0.05 by 2-tailed Student’s t test. Scale bars: 
50 μm
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with lenti-shAbat (Figure 3C). Histological analysis of  knee joint tissue sections showed a decrease in 
OARSI score and preservation of  cartilage area because of  lenti-shAbat treatment (Figure 3, D and E). 
Subchondral bone sclerosis is another feature of  OA, and we found that lenti-shAbat treatment result-
ed in lower levels of  sclerosis than those observed in lenti-GFP–infected control mice joints (Figure 3F 
and Supplemental Figure 5, A and B).
Immunohistochemistry was performed to examine the expression of  matrix proteins (Prg4, Col10a1) 
and the catabolic enzyme Mmp13. Preservation of  Prg4 expression was apparent in the superficial layer 
of  articular cartilage in the lenti-shAbat–infected knee joints at 10 weeks after MLI, whereas limited Prg4 
staining was evident in articular cartilage from control knees. Moreover, the expression of  Col10A1 and 
Mmp13 was also substantially diminished in lenti-shAbat infected cartilage compared with the abundant 
expression of  Col10A1 and Mmp13 observed in the damaged knee cartilages of  control mice infected with 
the lenti-GFP virus (Figure 3G). Together, these findings strongly suggest that Abat inhibition maintains 
chondrocyte homeostasis, protects against cartilage degeneration, and attenuates subchondral bone sclero-
sis in injury-induced OA, implicating Abat as a potential pharmacological target to treat OA.
Vigabatrin treatment protects against injury-induced OA progression in mice. Vigabatrin is an FDA-ap-
proved drug that specifically blocks Abat activity and is used clinically to increase GABA levels in 
neural cells (35–37). Therefore, vigabatrin was added to primary articular chondrocyte cell cultures 
to determine whether pharmacological inhibition of  Abat could maintain cellular homeostasis. To 
determine the effects of  vigabatrin in articular chondrocytes, GABA concentrations were measured 
in murine primary chondrocyte cultures following vigabatrin treatment. We found that vigabatrin 
increased GABA levels in articular chondrocytes as expected (Supplemental Figure 6A). Moreover, 
similar to lenti-shAbat treatment, vigabatrin significantly reduced mitochondrial respiration in chon-
drocyte cultures (Figure 4A and Supplemental Figure 7), and importantly, vigabatrin inhibited IL-1β–
mediated induction of  the catabolic genes Runx2, Mmp13, and Col10a1 in articular chondrocytes (Fig-
ure 4B). To further investigate whether pharmacological blockage of  Abat activity by vigabatrin in vivo 
could modify disease progression in injury-induced OA, MLI surgery was performed on 10-week-old 
male mice, and vigabatrin was administered daily through intraperitoneal injection at a concentration 
of  50 mg/kg or 200 mg/kg up to 10 weeks following surgery. The vigabatrin injection regime signifi-
cantly increased GABA concentrations in brain tissue as expected (Supplemental Figure 6B), con-
firming the pharmacological activity of  vigabatrin in vivo. At the lower dose of  50 mg/kg, vigabatrin 
did not show a protective effect on articular cartilage destruction based on histological examination 
(Supplemental Figure 8). Strikingly, administration of  vigabatrin at 200 mg/kg for 6 weeks following 
MLI surgery completely blocked the development of  an injury-induced OA phenotype. The apparent 
articular cartilage surface fibrillation, overall reduced articular cartilage thickness, and increased sub-
chondral bone sclerosis MLI induced was not observed in the vigabatrin-treated mice. By 10 weeks, 
MLI-induced cartilage damage was more advanced, with pronounced subchondral bone sclerosis in 
control mice injected with PBS. In contrast, cartilage tissue integrity was maintained by vigabatrin 
treatment at 200 mg/kg and subchondral sclerosis was not observed (Figure 4, C and D, and Supple-
mental Figure 9). Consistent with histological observations, OARSI scoring showed reduced scores, 
and cartilage area was also maintained in vigabatrin-treated mice at both 6 and 10 weeks following 
MLI (Figure 4, E and F), demonstrating that Abat inhibition by vigabatrin blocked the development of  
OA in mice following MLI surgery. Moreover, in contrast with the joints harvested from PBS-treated 
mice, vigabatrin treatment preserved Prg4 expression in the superficial layer of  cartilage tissue, and 
minimal expression of  Mmp13 and Col10A1 in cartilage tissue was observed (Figure 4G). Together, 
these data define Abat as a promising, novel target for the prevention of  OA.
Discussion
Previously we showed that the expression of  the DNA methyltransferase Dnmt3b is reduced in both murine 
and human articular cartilage in the context of  OA. Through loss- or gain-of-function experiments, we 
established an important mechanistic role for Dnmt3b in maintaining cartilage homeostasis (20). Because 
DNA methylation is widespread throughout the genome, multiple downstream targets are likely affected 
via changes in methylation levels within enhancers, promoters, and intronic and exonic regions in the gene 
body and in intervening regions of  DNA remote from a gene. As a starting point, we focused on genes 
whose expression was significantly altered by Dnmt3b LOF and that also displayed changes in methylation 
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patterns in their promoters. Gene ontology analysis of  these 44 genes revealed that cell metabolic pathways 
were a common target. In the current study, we establish one of  these genes, Abat, as a novel target involved 
in the regulation of  chondrocyte mitochondria function and the pathogenesis of  OA.
Abat is an enzyme that catalyzes the conversion of  GABA into succinic semialdehyde, which is sub-
sequently oxidized to succinate, a key intermediate in the TCA cycle (34). As we showed that Abat is 
increased in OA in both mice and humans, we subsequently used a series of  gain- and loss-of-function 
approaches to determine whether Abat is mechanistically involved in the development of  OA. We provide 
in vitro and in vivo evidence that overexpression of  Abat leads to chondrocyte hypertrophy, a catabolic 
phenotype, increased mitochondria respiration, and acceleration of  the development of  OA in mice. In 
contrast, Abat inhibition, in vitro and in vivo, maintains cartilage homeostasis, reduces mitochondrial res-
piration, and attenuates the development of  OA following joint injury. Finally, vigabatrin, an irreversible 
small-molecule inhibitor of  Abat, substantially prevented development of  OA in mice following MLI sur-
gery.
Recent studies provided increasing evidence that OA is associated with changes in chondrocyte homeosta-
sis that involve alterations in matrix gene expression and mitochondrial function. Specifically, healthy articular 
chondrocytes maintain a homeostatic state and primarily use glycolysis for energy production (25). In contrast, 
hypertrophic chondrocytes in the growth plate rely more on oxidative phosphorylation and mitochondrial 
function to generate ATP (38). Bone morphogenetic protein 2 (BMP2) treatment, which stimulates chon-
drocyte maturation and hypertrophy in vitro, also stimulates mitochondrial oxidative phosphorylation (25). 
Although a correlation has been established between oxidative phosphorylation and chondrocyte hypertrophy, 
it remains unclear whether increased mitochondrial respiration is a primary cause of chondrocyte maturation 
and is involved in the pathogenesis of OA. To our knowledge, we provide the first genetic evidence in this study 
that upregulation of cellular metabolism through Abat causes chondrocyte catabolism and leads to OA pro-
gression in mice. We show that overexpression of Abat in chondrocytes, as expected, enhances mitochondrial 
respiration and results in increased expression of catabolic and hypertrophy-related genes. Conversely, Abat 
inhibition attenuates the expression of catabolic and hypertrophy-related genes in IL-1β–treated articular chon-
drocytes, reduces mitochondrial respiration, and slows the progression of OA in mice following MLI surgery. 
The current findings with Abat GOF and LOF are consistent with our previous findings showing that suppres-
sion of mitochondrial respiration reduced articular chondrocyte hypertrophy (20). Altogether, these findings 
suggest a connection among Abat, mitochondrial function, cartilage catabolism, and the development of OA. 
In addition to energy metabolism, Abat regulates mitochondrial nucleoside metabolism and contributes to 
neurological disorders (27). It will be worthwhile to investigate whether nucleoside metabolism is directly asso-
ciated with chondrocyte mitochondrial metabolism and OA phenotype in future studies.
In this study, lentiviral vectors were injected into murine knee joints, which would have altered the 
expression of  Abat in synovial tissues, meniscus, and other ligamentous tissues. Although there were 
no obvious histological changes in these tissues, we did not examine these cells for changes in energy 
metabolism or gene expression. Because Abat targets an intracellular molecular process, it is unlikely that 
the molecular events in cartilage were secondary to signals from the synovium, meniscus, or ligament 
tissues. This is consistent with our finding that similar alterations in the anabolic versus catabolic balance 
in cartilage were observed in the in vivo and in vitro gain- and loss-of-function experiments. Because mice 
with Abat gene deletions are not currently available, our results provide the first genetic evidence to our 
knowledge demonstrating a functional role for Abat in chondrocytes, both in vivo and in vitro. Given its 
general importance in mitochondrial metabolism, inducible Abat gene deletion mice will be an extremely 
valuable tool to confirm the specific role of  Abat in cartilage and other tissues, including meniscus cells, 
synovial fibroblasts, and osteoblasts.
Abat is the rate-limiting enzyme that mediates glutamine amino transformation through a GABA 
Figure 3. Abat inhibition attenuates chondrocyte hypertrophy and protects cartilage degeneration following surgical induction of OA. (A) Mitochon-
drial respiration was measured in primary articular chondrocytes treated with lenti-shAbat (Abat LOF) or lenti-GFP (Ctrl) (n = 8). (B) Real-time qPCR 
analyses of gene expression from articular chondrocytes transduced with either lenti-shAbat (Abat LOF) or control virus following IL-1β treatment (n = 
3). (C) Representative images of histological sections from control or Abat LOF knee joints at 10 weeks following MLI surgery (n = 7). Quantification of 
histological assessment by OARSI scoring (D) and cartilage area (E) (n = 7). (F) BV/TV ratios of tibial subchondral bone were calculated from the micro-CT 
images (n = 7). (G) Immunohistochemical analyses for Prg4, Mmp13, and Col10A1 on knee sections of control and Abat LOF cartilage. *P < 0.05 by 2-tailed 
Student’s t test (A and D–F) and ANOVA with post hoc test (B). Scale bars: 50 μm.
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Figure 4. Vigabatrin attenuates chondrocyte hypertrophy and protects against injury-induced OA progression. (A) Mitochondrial respiration was 
measured in primary articular chondrocytes treated with PBS or vigabatrin (n = 8). (B) Real-time qPCR analyses of gene expression from articular 
chondrocytes pretreated with PBS and vigabatrin (100 μM) following IL-1β treatment (n = 3). (C) Representative images of histological sections of 
PBS-treated and vigabatrin-treated (200 mg/kg) knee joints at 6 and 10 weeks following MLI surgery (n = 5). (D) BV/TV ratios of tibial subchondral 
bone were calculated from the micro-CT images (n = 7). Quantification of histological assessment by OARSI scoring (E) and cartilage area (F) (n = 7). (G) 
Immunohistochemical analyses for Prg4, Mmp13, and Col10A1 on knee sections of PBS- and vigabatrin-treated cartilage 10 weeks after MLI. *P < 0.05 
by 2-tailed Student’s t test (A and D) and ANOVA with post hoc test (B, E, and F). Scale bars: 50 μm.
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intermediate to synthesize succinate, which enters the TCA cycle to facilitate energy production through 
mitochondrial oxidative phosphorylation (26, 34). Other sources of  succinate for the TCA cycle include 
glucose and lipid metabolism (39). Our findings indicate that Abat-mediated glutamine metabolism is a 
potentially important source of  succinate in articular chondrocytes because inhibition of  Abat had a robust 
effect on articular chondrocyte energy metabolism and had an important role in the maintenance of  chon-
drocyte homeostasis. However, our findings did not rule out a role for glucose and lipid metabolism as a 
source of  succinate production for use in the TCA cycle.
The most striking finding in this study is that vigabatrin significantly blocked the development of  OA in 
mice with MLI. As an FDA-approved inhibitor of  Abat activity that is used to prevent seizures, the kinetics 
(40–42) have been well studied and documented in different species, including mice, rats, monkeys, and 
humans (43). We confirmed the inhibitory effect of  vigabatrin in brain tissues by measuring an increase 
in GABA concentrations in harvested brain tissue and found that both 50 mg/kg and 200 mg/kg dosages 
were effective, and neither caused any obvious side effects. However, only mice with 200 mg/kg systemic 
vigabatrin injection displayed a protective effect on cartilage tissue in vivo, suggesting that higher systemic 
concentrations are required to get an enzyme-inhibitory concentration of  vigabatrin into articular chondro-
cytes in the knee joint. Therefore, other methods of  administration of  vigabatrin or alternative molecular 
or pharmaceutic approaches to target Abat or other key points of  articular chondrocyte metabolism are 
potential therapeutic approaches. Because pain is a significant clinical symptom in patients with OA, it will 
be worthwhile to examine the pain response under the vigabatrin treatment as well.
Although lenti-shAbat attenuated the onset of  OA in mice with MLI, the effect was partial and much 
less than was observed with vigabatrin. Fluorescent imaging of  lenti-GFP–infected articular cartilage 
demonstrated that only 40% of  articular chondrocytes were infected. Because Abat works on cell metabo-
lism in a cell-autonomous manner, the ability of  lenti-shAbat to block succinate production and decrease 
mitochondrial oxidative phosphorylation is dependent on the efficacy of  the lentiviral infection. In con-
trast, as an irreversible small-molecule inhibitor that is delivered systemically, vigabatrin appears to have 
more profound effects.
In addition to its role in energy production, succinate is an intracellular stimulator of  inflammatory sig-
naling (44, 45). In various cell types, such as dendritic cells, macrophages, and cancer cells, succinate stabiliz-
es HIF-1α under normoxia conditions and activates IL-1β expression through direct binding to the proximal 
gene promoter (46–48). In synovial fibroblasts, succinate treatment was found to induce NLRP3-mediated 
inflammasome activation and increase the intracellular inflammatory responses. However, this inflamma-
tion could be attenuated by inhibition of  succinate levels in cell cultures (49). Of  note, MLI surgeries caused 
inflammation in synovium tissue, whereas lenti-shAbat and vigabatrin treatment reduced the inflammatory 
response (Supplemental Figure 1D, Supplemental Figure 4B, and Supplemental Figure 10). Other studies 
also indicate that vigabatrin inhibits the mammalian target of  rapamycin (mTOR) pathway in cell cultures 
and in murine models (50). The mTOR pathway has been shown as an important regulator in skeletal 
growth and chondrocyte differentiation in mice (51–53), and inhibition of  mTOR has been shown to be 
associated with enhanced autophagy (54, 55). Thus, the ability of  vigabatrin to prevent the development of  
OA following knee injury in mice could be related in part through alternative mechanisms that include inhi-
bition of  succinate-mediated inflammation and increased autophagy via mTOR inhibition.
In conclusion, our potentially novel body of  research has established Abat as an important downstream 
target of  Dnmt3b and as a critical regulator of  cellular metabolism and chondrocyte hypertrophy/catabo-
lism. The chondroprotective effects of  Abat inhibition on injury-induced OA implicate Abat, via its effects 
on cellular metabolism, as a promising pharmacological target for OA treatment.
Methods
Mice. Male 10-week-old C57BL/6J wild-type mice were purchased from The Jackson Laboratory (catalog 
000664). MLI surgery was performed on the right knee as previously described (20). Sham surgery was 
performed on knees of  the left limbs as a control. Lentivirus containing 106 transducing units (10 μl) was 
injected into the knee joint immediately after MLI to either knock down or overexpress Abat. Scramble len-
tivirus was used as a control. To inhibit Abat activity in vivo, vigabatrin (50 mg/kg and 200 mg/kg, Tocris, 
0808) was administered by intraperitoneal injection to mice daily following MLI surgery for 6 or 10 weeks.
Murine knee joint analysis. Knee joint samples were harvested at different time points for histological and 
micro-CT analyses. Specifically, knee joints were harvested 4 weeks after MLI in Abat overexpression treat-
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ment groups, 10 weeks for Abat inhibition treatment, or 6 and 10 weeks for vigabatrin-treated mice. After 
neutral-buffered formalin fixation and EDTA decalcification, knee joints were processed, paraffin embed-
ded, and sectioned at 5 μm. Safranin-O/Fast Green (Sigma, F7258) and Alcian Blue Hematoxylin/Orange 
G (Sigma, O7252) stainings were performed to analyze knee joint tissue architecture. OA severity was 
scored using the established OARSI scoring system (56). Immunohistochemistry was performed on sec-
tions using citrate buffer antigen retrieval and colorimetric development methodologies. Antibodies against 
Prg4 (1:200, Abcam, ab28484), Mmp13 (1:200, Abcam, ab39012), Col10A1 (1:100, Quartet, 1-CO097-05), 
FLAG (1:1000, Origene, TA150014), and GFP (1:200, Abcam, ab13970) were used. DAB reagent (Vector 
Laboratories, SK-4100) was used for peroxidase substrate reaction. Counterstaining was performed using 
hematoxylin or methyl green. Anti-GFP secondary antibody conjugated with Alexa Fluor 488 (1:100, Invi-
trogen, A21311) was used, and fluorescence was analyzed on a Zeiss microscope.
Micro-CT analyses were performed on mouse knee joints before decalcification using a VivaCT 40 
scanner (Scanco USA Inc.), using a protocol consisting of  high-resolution (10.5 microns) x-ray energy set-
tings of  55 kVp, 145 μA, and 300 ms integration time. BV/TV of  tibial subchondral bone as well as trabec-
ular properties, including trabecular thickness, trabecular spacing, and trabecular number, were analyzed 
as previously described using the Scanco analysis software (57). In addition to the whole tibial plateau, 
analyses were also conducted on the medial tibial plateau to reveal more apparent pathological changes 
attributable to MLI.
Primary articular chondrocyte isolation and culture. Primary articular chondrocytes were isolated from 
murine femoral heads and human cartilage as previously described (20). Briefly, cells were harvested from 
cartilage tissue by 4–6 hours of  collagenase P (0.5 mg/ml, Roche, 11249002001) digestion for mice and 
14–16 hours of  collagenase P (0.035%) digestion for human tissue. Following digestion, cells were seed-
ed at a density of  5 × 105, 2.5 × 105, or 5 × 104 cells/well in 12-, 24-, or 96-well plates, respectively. For 
the Dnmt3b LOF experiments, chondrocytes isolated from Dnmt3bfl/fl mice were transduced with adenovi-
rus expressing GFP (control) or Cre (Dnmt3b LOF) at a multiplicity of  50. Lenti–shAbat-GFP (Origene, 
TL508059V) transduction at a multiplicity of  10 for 24 hours or vigabatrin (100 μM) pretreatment for 30 
minutes was used to knock down Abat expression or inhibit Abat activity, followed by IL-1β treatment (1 
ng/ml, R&D Systems, 201-LB-005) for 24 hours. Lenti-Dnmt3b (Origene, MR225598L1V) and lenti–Abat-
Flag (ABM, LVP457865) at a multiplicity of  5 were used to induce Dnmt3b and Abat overexpression in 
primary articular chondrocytes.
Full-thickness sections of human articular cartilage were removed from the femoral condyles and tibial 
plateaus of specimens obtained following total knee replacement surgery, diced into 2-mm cubes, and digested 
at 37°C for 90 minutes by 0.4% pronase (Roche, 10165921001) and 14 hours by 0.035% collagenase P (Roche, 
11249002001). The tissue from the area of the joint surface with severe degeneration was used as OA samples, 
and tissue from the cartilage with normal appearance was used as nondiseased samples (20). Cells were plated 
at a density of 100,000 cells/cm2 and treated with IL-1β (10 ng/ml, Roche, 201-LB-005) for 48 hours.
Mitochondria stress test. Mitochondrial respiration profile, particularly OCR, was measured according 
to the manufacturer’s instructions (Agilent). Briefly, primary articular chondrocytes with Abat overexpres-
sion via lenti-Abat as well as Abat inhibition by lenti-shAbat and vigabatrin were plated in XF96 plates 
at 5 × 104 cells/well with XF Assay Medium Modified DMEM (Seahorse, 101022-100). Oligomycin and 
FCCP were used at a final concentration of  5 μM and 1 μM, respectively, to manipulate the mitochondrial 
response. Antimycin and rotenone (Agilent) were used to suppress the mitochondrial respiration. At the 
end of  the assays, protein concentrations were measured for normalization.
ChIP assay. ATDC-5 cells (1 × 107) purchased from MilliporeSigma (catalog 99072806) were harvested 
and fixed with formaldehyde for ChIP assays. Chromatin was fragmented by sonication to shear DNA 
to 200–500 bp in size. Chromatin fragments were immunoprecipitated using the Dnmt3b antibody (1:50, 
Abcam, ab2851) while Histone H3 and IgG antibodies (Cell Signaling, 56383) were used as positive and 
negative controls, respectively. After reverse cross-linking of  protein DNA, the enrichment of  Abat DNA 
fragments during immunoprecipitation was analyzed by standard PCR and quantitative real-time PCR. 
Primer 1 sequences (within CpG island) for Abat promoter used for PCR were forward, 5′-GGAAATC-
CCTCCCTCGTTTAG-3′, and reverse, 5′-GGAAAGGGAGATGAGAAAG-3′; primer 2 sequences (away 
from CpG island) were forward, 5′-GCTAGCCGCTTAAACTCATCTA-3′, and reverse, 5′-GAGATTG-
GAAAGGAGAAGG-3′.
GABA concentration measurement. Vigabatrin efficacy in vivo and in vitro was examined by the GABA 
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ELISA Kit (LSBio, LS-F4121) using brain tissue isolated from vigabatrin-treated mice and cell lysates from 
vigabatrin-treated articular chondrocytes according to the manufacturer’s instructions.
Methylation qPCR. Methylation qPCR for Abat was performed according to the manufacturer’s instruc-
tions (Qiagen, 335452). Genomic DNA isolated from Dnmt3b LOF and control articular chondrocytes 
was enzymatically digested by methylation-sensitive or methylation-dependent enzymes separately. The 
enzyme-digested genomic DNA was then used for qPCR, and the primers for Abat methylation (CpG 
island 104232) were obtained from Qiagen (EPMM104232).
Real-time PCR and Western blot. RNA was isolated from primary articular chondrocytes or murine 
cartilage tissue using the RNeasy Mini Kit (Qiagen, 74134). cDNA was synthesized using iScript kit 
(Bio-Rad, 1708841), and reverse transcription PCR was performed according to the manufacturer’s 
instructions. Primer sequences for Runx2, Mmp13, Col10a1, Abat, Abatb, ABAT, and GAPDH are shown 
in Table 1. Western blot analyses were performed on protein lysates from either primary articular 
chondrocytes or murine cartilage tissue using the primary antibodies Abat (1:1000, LSBio, LS-B14889) 
and β-actin (1:4000, MilliporeSigma, 2228).
Statistics. All data are presented as the mean ± SD. The comparisons between 2 groups were analyzed 
by 2-tailed Student’s t test. Multiple-factorial 1-way ANOVA was used to compare multiple groups followed 
by post hoc tests. P < 0.05 was considered statistically significant.
Study approval. Human knee articular cartilage tissue was obtained from surgeons at Washington Univer-
sity Department of  Orthopedic Surgery following total knee replacement surgery. All studies involving this 
tissue, which was used to generate primary articular chondrocytes for in vitro experiments, were approved 
by Washington University Human Research Protection Office (IRB ID 201104119). MLI procedures were 
conducted in compliance with the Association for Assessment and Accreditation of  Laboratory Animal 
Care–accredited Washington University IACUC and the NIH guidelines.
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